hederagenin−3−O−[β−D−xylopyranosyl−(1→3)]−[α−L−rhamnopyranosyl−(1→2)]−α−L−arabinopyranoside | 29321-28-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: hederagenin−3−O−[β−D−xylopyranosyl−(1→3)]−[α−L−rhamnopyranosyl−(1→2)]−α−L−arabinopyranoside
• 英文别名: hederagenin 3-O-α-L-arabinopyranosyl-(1->3)-α-L-rhamnopyranosyl-(1->2)-α-L-arabinopyranoside；hederagenin-3-O-α-L-arabinopyranosyl-(1->3)-α-L-rhamnopyranosyl-(1->2)-α-L-arabinopyranoside；3-O-(α-L-arabinopyranosyl-(1→3)-α-L-rhamnopyranosyl-(1→2)-α-L-arabinopyranosyl)hederagenin；3-O-α-L-arabinopyranosyl-(1→3)-α-L-rhamnopyranosyl-(1→2)-α-L-arabinopyranosylhederagenin；3-O-(α-L-arabinopyranosyl-(1-3)-α-L-rhamnopyranosyl-(1-2)-α-L-arabinopyranosyl)-hederagenin；Clemontanoside-C；(4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-3-[(2S,3R,4R,5S,6S)-3,5-dihydroxy-6-methyl-4-[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
• CAS: 29321-28-6；30994-75-3；72629-76-6；80666-65-5
• 化学式: C₄₆H₇₄O₁₆
• 分子量: 883.084
• InChiKey: IAGSHEHQJJTLLR-UXDKCJHBSA-N

物化性质

• 沸点：
  975.1±65.0 °C(Predicted)
• 密度：
  1.38±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  62
• 可旋转键数：
  8
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  255
• 氢给体数：
  9
• 氢受体数：
  16

反应信息

• 作为反应物：
  描述：

  hederagenin−3−O−[β−D−xylopyranosyl−(1→3)]−[α−L−rhamnopyranosyl−(1→2)]−α−L−arabinopyranoside 在 中性纤维素酶 McIlvaine buffer 作用下， 以28 mg的产率得到Alpha-常春藤苷
  参考文献：
  名称：

  Kimata, Hiroko; Nakashima, Taeko; Kokubin, Setsuko, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 6, p. 1998 - 2005

  摘要：

  DOI：
• 作为产物：
  描述：

  mukurozi-saponin Y₂ 在 甲醇 、 氢氧化钾 作用下， 反应 1.0h， 生成 hederagenin−3−O−[β−D−xylopyranosyl−(1→3)]−[α−L−rhamnopyranosyl−(1→2)]−α−L−arabinopyranoside
  参考文献：
  名称：

  Kimata, Hiroko; Nakashima, Taeko; Kokubin, Setsuko, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 6, p. 1998 - 2005

  摘要：

  DOI：

文献信息

• Vaccine Compositions For Marburg Virus
  申请人：Pathak Ashish Kumar

  公开号：US20120136142A1

  公开（公告）日：2012-05-31

  Methods and immunogenic compositions for generating an immune response against Marburg virus are provided. The immunogenic composition includes antigens obtained from a Marburg viral strain in combination with an oleanolic acid triterpene adjuvant.

  本发明提供了用于产生针对马尔堡病毒的免疫反应的方法和免疫原组合物。该免疫原组合物包括从马尔堡病毒株中获得的抗原，结合油酸三萜佐酸类佐剂。
• Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof
  申请人：Young Jeffrey

  公开号：US20050287230A1

  公开（公告）日：2005-12-29

  The present invention is a method of producing ginsenoside comprising the steps of: (a) producing a predetermined quantity of ginseng dialcohol from an extraction process of ginseng dialcohol; (b) reacting the ginseng dialcohol with a predetermined quantity of acetobromo-α-D-glucose under a predetermined condition; and (c) obtaining a predetermined quantity of ginsenoside Rh 2 . The present invention also provides a composition for enhancing the immune system of a living object comprising a quantity of ginsenoside, a quantity of ursolic acid and a quantity of shikonin. The composition may also comprise a quantity of panaxans, astragalan, and/or lentinan. The ginsenoside 20(R)-Rh 2 , ursolic acid, shikonin, panaxans, astragalan and lentinan have an effective range between 0.001 mg/kg and 0.1 mg/kg, 0.5 mg/kg and 10 mg/kg, 0.5 mg/kg and 10 mg/kg, 0.1 mg/kg and 1 mg/kg, 0.1 mg/kg and 1 mg/kg, and 0.1 mg/kg and 1 mg/kg respectively.

  本发明涉及一种生产人参皂苷的方法，包括以下步骤：（a）从人参二醇的提取过程中生产出预定量的人参二醇；（b）在预定条件下将人参二醇与预定量的乙酰溴-α-D-葡萄糖反应；（c）获得预定量的人参皂苷Rh2。本发明还提供了一种增强生物体免疫系统的组合物，包括一定量的人参皂苷、一定量的熊果酸和一定量的赤芍。该组合物还可以包括一定量的人参皂苷、黄芪苷和/或香菇多糖。人参皂苷20（R）-Rh2、熊果酸、赤芍、人参皂苷、黄芪苷和香菇多糖在0.001 mg/kg至0.1 mg/kg、0.5 mg/kg至10 mg/kg、0.5 mg/kg至10 mg/kg、0.1 mg/kg至1 mg/kg、0.1 mg/kg至1 mg/kg和0.1 mg/kg至1 mg/kg之间具有有效范围。
• METHOD FOR PRODUCING GLYCOSIDE AGLYCONE
  申请人：Isobe Yosuke

  公开号：US20100191003A1

  公开（公告）日：2010-07-29

  It is intended to provide a method for producing aglycone from a glycoside efficiently at low cost without using an acid catalyst or an organic solvent. The method for producing aglycone, characterized by bringing a glycoside into contact with high temperature high pressure water. The temperature of the high temperature high pressure water is generally from 100 to 374° C., preferably from 140 to 320° C., more preferably from 200 to 300° C. The pressure of the high temperature high pressure water may be not lower than the saturated water vapor pressure at the temperature, i.e., a pressure at which the liquid state is maintained.

  本发明旨在提供一种在不使用酸催化剂或有机溶剂的情况下，以低成本高效地从糖苷中产生原芸香苷的方法。该方法的特点是将糖苷与高温高压水接触，从而产生原芸香苷。高温高压水的温度通常在100到374℃之间，最好在140到320℃之间，更好地在200到300℃之间。高温高压水的压力可能不低于该温度下饱和水蒸气压力，即液态得以维持的压力。
• COMPOSITION COMPRISING ISCOM PARTICLES AND LIVE MICRO-ORGANISMS
  申请人：Morein Bror

  公开号：US20110081378A1

  公开（公告）日：2011-04-07

  Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.

  Iscom颗粒可用作制备抗原成分的佐剂，该成分包括活体微生物和/或死亡微生物和/或抗原分子。该成分可以包括至少一个Iscom颗粒和一个或多个活体微生物和/或死亡微生物和/或抗原分子。一种工具包可以包括至少一个隔间，其中包含至少一个生物体和至少一个隔间，其中包含至少一个Iscom颗粒。
• SAPONIN NANO MICELLE, PREPARING METHOD, APPLICATION AND PHARMACEUTICAL COMPOSITION THEREOF
  申请人：FUJIAN SOUTH PHARMACEUTICAL CO. LTD.

  公开号：US20150297727A1

  公开（公告）日：2015-10-22

  A saponin nano micelle, preparing method, application and pharmaceutical composition thereof is disclosed in the present invention. The saponin nano micelle comprises one or more of saponins represented by formula 1, in which, R 1 and R 2 are independently —H or a hydrophilic group, R 3 is —H or —OH, R 4 is a lipophilic group. The preparing method of the saponin nano micelle is that mixing the saponin with an organic solvent which can dissolve saponin, and then removing the organic solvent. The saponin micelle acts as a convey medium of the drug ingredients, and can replace conventional drug carriers such as pharmaceutical solubilizers or polymeric micelle, which has high safety and great significance. The pharmaceutical ingredients can prolong circulation time and biological half-life of drug in the blood, and increase the accumulation of drug in lesions, and reduce adverse reactions.

  本发明公开了一种皂苷纳米胶束，其制备方法、应用及制药组合物。该皂苷纳米胶束包含式1所代表的一个或多个皂苷，其中R1和R2独立地为—H或亲水基团，R3为—H或—OH，R4为亲脂基团。该皂苷纳米胶束的制备方法是将皂苷与能溶解皂苷的有机溶剂混合，然后去除有机溶剂。皂苷胶束作为药物成分的传递介质，可以替代传统的药物载体，如药物溶解剂或聚合物胶束，具有高安全性和重要意义。制药成分可以延长药物在血液中的循环时间和生物半衰期，增加药物在病变部位的积累，并减少不良反应。